Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 56Leukemia, Myeloid, Acute 38Breast Neoplasms 38Lymphoma, Large B-Cell, Diffuse 37Multiple Myeloma 31Lymphoma, Non-Hodgkin 30Burkitt Lymphoma 30Lymphoma 28Myelodysplastic Syndromes 25Triple Negative Breast Neoplasms 23Lymphoma, B-Cell 22Hematologic Neoplasms 22Recurrence 21Lymphoma, Follicular 20Melanoma 16Leukemia, Lymphocytic, Chronic, B-Cell 15Leukemia 14Ovarian Neoplasms 13Neoplasm Metastasis 13Hodgkin Disease 13Neoplasms 12Leukemia, Biphenotypic, Acute 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Pancreatic Neoplasms 11Neuroblastoma 11Leukemia, Myelomonocytic, Chronic 11Lymphoma, Mantle-Cell 10Graft vs Host Disease 10Carcinoma, Non-Small-Cell Lung 10Sarcoma 9

Interventions

Carboplatin 4pertuzumab 2durvalumab 2Tretinoin 2Trastuzumab 2Standard of Care 2Paclitaxel 2Oxaliplatin 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1toripalimab 1tislelizumab 1talazoparib 1sarilumab 1relugolix 1regorafenib 1pexidartinib 1pembrolizumab 1patritumab 1olaparib 1niraparib 1nimotuzumab 1neratinib 1ganitumab 1enzalutamide 1dostarlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Pathologic Complete Response × Cyclophosphamide × Clear all
NCT04314219 2025-03-13

PTCy-PMAT

King Faisal Specialist Hospital & Research Center

Phase 3 Recruiting
264 enrolled
LymphoidOther hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡